Takeda and Moderna Announce Plans to Transfer Marketing Authorization for Spikevax™ COVID-19 Vaccine in Japan to Moderna
yahoo.com
news
2022-05-31 07:56:00

− Moderna to become marketing authorization holder in Japan and be responsible for all import, local regulatory, development, quality assurance and commercial activities for Spikevax™ from 1st August 2022

− Companies concluded memorandum of understanding that Takeda will continue to provide distribution support for the Moderna COVID-19 vaccines for a transitional period.

CAMBRIDGE, Mass. & OSAKA, Japan, May 31, 2022--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Takeda (TSE:4502/NYSE:TAK) announced to transfer the marketing authorization in Japan for Moderna's COVID-19 vaccine Spikevax™ (mRNA-1273) from Takeda to Moderna in Japan as of August 1, 2022.
